Articoli con mandati relativi all'accesso pubblico - Allan RettieUlteriori informazioni
Non disponibili pubblicamente: 6
CYP2C9 genotype‐dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R‐and S‐warfarin and their oxidative metabolites
DR Flora, AE Rettie, RC Brundage, TS Tracy
The Journal of Clinical Pharmacology 57 (3), 382-393, 2017
Mandati: US National Institutes of Health
Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies
K Roellecke, EL Virts, R Einholz, KZ Edson, B Altvater, C Rossig, ...
Gene therapy 23 (7), 615-626, 2016
Mandati: US National Institutes of Health
Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome P450 4Z1
JP Kowalski, MG McDonald, RD Pelletier, H Hanenberg, C Wiek, ...
Journal of medicinal chemistry 63 (9), 4824-4836, 2020
Mandati: US National Institutes of Health
The CYP4 family
AE Rettie, EJ Kelly
Mandati: US National Institutes of Health
Structure–activity relationships for CYP4B1 bioactivation of 4-ipomeanol congeners: Direct correlation between cytotoxicity and trapped reactive intermediates
JP Kowalski, MG McDonald, D Whittington, M Guttman, M Scian, ...
Chemical Research in Toxicology 32 (12), 2488-2498, 2019
Mandati: US National Institutes of Health
VKCFD2–from clinical phenotype to molecular mechanism
KJ Czogalla, M Watzka, J Oldenburg
Hämostaseologie 36 (S 02), S13-S20, 2016
Mandati: German Research Foundation
Disponibili pubblicamente: 82
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
Mandati: US National Institutes of Health
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
Mandati: US National Institutes of Health
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ...
Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008
Mandati: US National Institutes of Health
CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant
MG McDonald, MJ Rieder, M Nakano, CK Hsia, AE Rettie
Molecular pharmacology 75 (6), 1337-1346, 2009
Mandati: US National Institutes of Health
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing
KE Caudle, AE Rettie, M Whirl‐Carrillo, LH Smith, S Mintzer, MTM Lee, ...
Clinical Pharmacology & Therapeutics 96 (5), 542-548, 2014
Mandati: US National Institutes of Health
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue
F Innocenti, GM Cooper, IB Stanaway, ER Gamazon, JD Smith, S Mirkov, ...
PLoS genetics 7 (5), e1002078, 2011
Mandati: US National Institutes of Health
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
AK Daly, AE Rettie, DM Fowler, JO Miners
Journal of personalized medicine 8 (1), 1, 2017
Mandati: US National Institutes of Health
Role of biotransformation in drug-induced toxicity: influence of intra-and inter-species differences in drug metabolism
TA Baillie, AE Rettie
Drug metabolism and pharmacokinetics 26 (1), 15-29, 2011
Mandati: US National Institutes of Health
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update
JH Karnes, AE Rettie, AA Somogyi, R Huddart, AE Fohner, CM Formea, ...
Clinical Pharmacology & Therapeutics 109 (2), 302-309, 2021
Mandati: US National Institutes of Health, National Health and Medical Research …
Cytochrome P450 ω-hydroxylases in inflammation and cancer
AL Johnson, KZ Edson, RA Totah, AE Rettie
Advances in pharmacology 74, 223-262, 2015
Mandati: US National Institutes of Health
Expression and characterization of CYP4V2 as a fatty acid ω-hydroxylase
M Nakano, EJ Kelly, AE Rettie
Drug metabolism and disposition 37 (11), 2119-2122, 2009
Mandati: US National Institutes of Health
CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase …
KZ Edson, AE Rettie
Current topics in medicinal chemistry 13 (12), 1429-1440, 2013
Mandati: US National Institutes of Health
Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11
KZ Edson, B Prasad, JD Unadkat, Y Suhara, T Okano, FP Guengerich, ...
Biochemistry 52 (46), 8276-8285, 2013
Mandati: US National Institutes of Health
CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p. H331P variant
M Nakano, EJ Kelly, C Wiek, H Hanenberg, AE Rettie
Molecular pharmacology 82 (4), 679-686, 2012
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software